Close Menu

hybridization

The Seattle firm saw consumables and collaboration revenues fall, however, the GeoMx spatial transcriptomics platform grew instrument revenue.

The Harvard spinout wants its instrumentation and reagent packages to ease the transition for labs interested in high-resolution imaging studies.

The firm touts a new hybridization probe design, which it says will enable small, focused panels that reduce sequencing costs and assay time.

The workflow combines Swift's Adaptase technology and RNA library kits with Arbor's myBaits technology for hybridization-based target enrichment of the virus.

These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.

The ePlex SARS-CoV-2 Test is exclusively for use on the company's ePlex sample-to-answer system, which has a global installed base of more than 500 as of the end of 2019.

The partners' "COVID-19 task force" will invest in ePlex molecular testing platforms from GenMark Diagnostics to quadruple UCSF's testing capacity.

The firm shipped research-use-only tests last week to key customers to validate the assay design using clinical samples.

The UK's Biosearch Technologies will distribute Arbor Biosciences' myBaits custom, targeted NGS panels to agricultural and seed breeding companies.

While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.